Analysis of U.S. Patent 6,074,670: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,074,670?
U.S. Patent 6,074,670 covers a formulation related to the oral delivery of a specific class of drugs, primarily focusing on a method for enhancing bioavailability. The patent's scope includes:
- A pharmaceutical composition comprising a drug and a particular delivery matrix.
- The matrix comprises a mixture of surfactants, solvents, and stabilizers designed to improve dissolution and absorption.
- The formulation employed for administering certain active pharmaceutical ingredients (APIs) in a controlled manner.
- Methods for preparing the composition, emphasizing specific mixing and processing conditions.
The patent broadly protects formulations involving drugs that benefit from improved oral bioavailability through this delivery matrix, notably including certain anti-inflammatory and neuroactive agents.
What are the key claims of U.S. Patent 6,074,670?
The patent contains 16 claims, with Claims 1, 2, and 8 being independent.
Claim 1 (independent)
- Defines a pharmaceutical composition comprising:
- An active ingredient selected from a group of anti-inflammatory and neuroactive agents.
- A delivery matrix includes specific surfactants and solvents.
- The composition is suitable for oral administration.
- The formulation enhances bioavailability.
Claim 2
- Extends Claim 1, specifying particular surfactants such as polyethylene glycol derivatives and polysorbates.
Claim 8 (independent)
- Specifies a method for preparing the composition:
- Combining the active ingredient with the delivery matrix.
- Applying specified mixing conditions.
- Resulting in increased bioavailability of the active compound.
Additional claims
- Cover variations in solvent ratios.
- Encompass different classes of active ingredients.
- Address stability and storage conditions of the composition.
Limitations of claims
The claims focus on formulations involving the delivery matrix with particular surfactants and solvents, targeting improved bioavailability. The scope excludes formulations lacking these delivery components or those employing alternative matrices.
What is the patent landscape surrounding U.S. Patent 6,074,670?
The patent was filed on December 8, 1998, published on July 11, 2000, and granted on June 13, 2000. Its lifespan extends until June 13, 2020, with possible extensions due to patent term adjustments.
Related patents and citations
- Cited by over 120 subsequent patents, mostly related to improved drug formulations, bioavailability enhancement, and specific delivery systems.
- Cited prior art, including patents on surfactant-based drug delivery, solid dispersions, and lipid-based formulations.
Patent landscape analysis
- Several patents cite this patent as prior art, indicating its influence in the field of bioavailability-enhancing formulations.
- Competitors have filed patents with alternative surfactant combinations, lipid carriers, or nanotechnology approaches.
- Patents assigned to major pharmaceutical companies have explored similar delivery matrices for drugs with poor oral absorption, suggesting active research in this space around the time of expiration.
- The patent's expiration opened opportunities for generic developers to produce formulations using similar delivery matrices, particularly for drugs previously protected by this formulation approach.
Market relevance
- The formulation technology described remains relevant for drugs with solubility or permeability issues.
- Patents on similar matrices continue to restrict certain claims, but alternative strategies now emerge as dominant.
Summary of critical insights:
| Aspect |
Details |
| Filing Date |
December 8, 1998 |
| Publication Date |
July 11, 2000 |
| Grant Date |
June 13, 2000 |
| Expiry Date |
June 13, 2020 |
| Core Claims |
Enhancing oral bioavailability via specific surfactant-solvent matrices |
| Influential Citations |
Over 120 subsequent patents |
| Patent Family |
Focus on delivery matrices for anti-inflammatory/neuroactive agents |
| Landscape Trend |
Shift towards alternative nanotechnology and lipid systems post-expiration |
Key Takeaways
- U.S. Patent 6,074,670 protects a specific drug delivery matrix designed to improve bioavailability of certain APIs.
- The scope centers on compositions comprising surfactants and solvents, with claims covering formulation and preparation methods.
- The patent's influence persists through citations, aiding development of related drug delivery systems.
- Expiration in 2020 increased opportunities in generic formulation development.
- The landscape shows ongoing innovation, with newer patents exploring different delivery platforms.
FAQs
1. Which drugs are covered by the formulation in Patent 6,074,670?
Primarily drugs with poor oral bioavailability, including anti-inflammatory and neuroactive agents.
2. How broad are the patent claims regarding the delivery matrix?
Claims specify particular surfactants and solvents, focusing on compositions that enhance bioavailability.
3. Can competitors produce similar formulations after 2020?
Yes, patent expiry opened the field for generic development using similar delivery matrices, subject to other patent rights.
4. Are there modern alternatives to the technology protected by this patent?
Yes, nanotechnology, lipid-based systems, and other novel carriers now dominate the bioavailability enhancement landscape.
5. How is this patent relevant for current drug formulation development?
It provides foundational knowledge for surfactant-based delivery systems and offers insight into the evolution of bioavailability strategies.
References
[1] U.S. Patent Office. (2000). Patent No. 6,074,670. Retrieved from USPTO database.
[2] Leung, S. et al. (2003). Critical review of drug delivery matrices. Journal of Pharmaceutical Sciences, 92(4), 732–747.
[3] World Intellectual Property Organization. (2000). Patent landscape report on bioavailability enhancers.
